Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
THW Stock Summary
Top 10 Correlated ETFs
THW
In the News
THW And THQ: Global Healthcare Exposure With A Double-Digit Yield
abrdn World Healthcare Fund provides exposure to top-tier healthcare holdings with a high distribution yield of over 10.7%. THW has a global focus with over 40% of their portfolio having exposure to companies based outside the U.S. or companies that get a large percentage of their revenue internationally.
Yes, You Can Retire On Dividends, 2 Fat Yields Up To 10%
The market's biggest secret is that you don't need to own a market-wide ETF to succeed. You don't need to sell your assets to fund your retirement. Reject that. Your retirement needs income; let the market pay your way.
Two +8% Yields To Buy And Never Let Go
The stock market is an incredible wealth builder for those with patience and long-term focus. We collect dividends through the seesaw and amplify our income through the art of compounding. Two monthly-pay closed-end funds to strengthen your financial flexibility in retirement – UTG and THW.
BME Vs. THW: A Distribution Cut Should Widen The Performance Gap
We had contrasting outlooks on the BlackRock Health Sciences Trust and abrdn World Healthcare Fund closed-end funds on our last coverage, with BME getting a "Buy" and THW getting a "Goodbye". BME has outperformed THW by 10% in total returns since then. We update our outlook and explain why one of these two gets a downgrade.
Weekly Closed-End Fund Roundup: November 26, 2023
19 out of 22 CEF sectors are positive on price, and 21 out of 22 sectors are positive on NAV. KYN/KMF merger completes. NXG Cushing Midstream Energy Fund rights offering begins.
Weekly Closed-End Fund Roundup: Tortoise Tender Results (November 19, 2023)
22 out of 22 CEF sectors positive on price and 21 out of 22 sectors positive on NAV. Tortoise tender offering results. Eaton Vance tender offer results.
5 Best CEFs This Month For 10% Yield (November 2023)
For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.
THW: abrdn Takes Over, Fund Drops To Massive Discount, But THQ Still Looking Better
abrdn has taken over the management of the former Tekla funds, and they've dropped to some meaningful discounts. Both the abrdn World Healthcare Fund and the abrdn Healthcare Opportunities Fund represent attractive investment opportunities, but I would tend to favor THQ. THW has a higher distribution rate when compared to THQ, which can have some appeal for some investors, but both funds will rely entirely on capital gains going forward.
5 Best CEFs This Month For 10% Yield (October 2023)
For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records, pay high distributions, and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.
ASGI Vs. UTF: Battle Of The High Yielders
ASGI Vs. UTF: Battle Of The High Yielders
THW Financial details
THW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-09-30
Metric | History | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | -0.31 | 2.07 | 2.48 | -2.04 | 1.02 | |
Net income per share | -0.35 | 2.03 | 2.44 | -2.09 | 0.99 | |
Operating cash flow per share | 0.67 | 1.27 | -1.59 | 1.62 | 1.18 | |
Free cash flow per share | 0.67 | 1.27 | -1.59 | 1.62 | 1.18 | |
Cash per share | 0.24 | 0.4 | 0.99 | 0.62 | 0.52 | |
Book value per share | 13.51 | 14.22 | 16.21 | 15.14 | 11.73 | |
Tangible book value per share | 13.51 | 14.22 | 16.21 | 15.14 | 11.73 | |
Share holders equity per share | 13.51 | 14.22 | 16.21 | 15.14 | 11.73 | |
Interest debt per share | 8.09 | 8.08 | 6.91 | 8.07 | 6.48 | |
Market cap | 405.3M | 429.92M | 573.95M | 385.82M | 446.69M | |
Enterprise value | 525.3M | 548.55M | 693.95M | 505.82M | 566.69M | |
P/E ratio | -37.99 | 7.06 | 6.74 | -6.14 | 11.87 | |
Price to sales ratio | -43.05 | 6.92 | 6.63 | -6.3 | 11.45 | |
POCF ratio | 19.94 | 11.26 | -10.37 | 7.96 | 9.96 | |
PFCF ratio | 19.94 | 11.26 | -10.37 | 7.96 | 9.96 | |
P/B Ratio | 0.99 | 1.01 | 1.01 | 0.85 | 1 | |
PTB ratio | 0.99 | 1.01 | 1.01 | 0.85 | 1 | |
EV to sales | -55.8 | 8.83 | 8.02 | -8.26 | 14.53 | |
Enterprise value over EBITDA | -49.24 | 9.01 | 8.15 | -8.32 | 15.06 | |
EV to operating cash flow | 25.85 | 14.37 | -12.54 | 10.44 | 12.64 | |
EV to free cash flow | 25.85 | 14.37 | -12.54 | 10.44 | 12.64 | |
Earnings yield | -0.03 | 0.14 | 0.15 | -0.16 | 0.08 | |
Free cash flow yield | 0.05 | 0.09 | -0.1 | 0.13 | 0.1 | |
Debt to equity | 0.59 | 0.56 | 0.42 | 0.53 | 0.54 | |
Debt to assets | 0.45 | 0.44 | 0.34 | 0.41 | 0.42 | |
Net debt to EBITDA | -11.25 | 1.95 | 1.41 | -1.97 | 3.19 | |
Current ratio | 1.27 | 11.56 | 0.12 | 4.08 | 1.66 | |
Interest coverage | -2.72 | 24.51 | 74.66 | -29.72 | 5.38 | |
Income quality | -1.9 | 0.63 | -0.65 | -0.77 | 1.19 | |
Dividend Yield | 0.1 | 0.1 | 0.08 | 0.13 | 0.11 | |
Payout ratio | -3.97 | 0.68 | 0.53 | -0.77 | 1.3 | |
Sales general and administrative to revenue | -0.1 | 0.02 | 0.01 | -0.02 | 0.03 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 10.37 | 25.48 | 29.83 | 26.71 | 16.14 | |
ROIC | -0.02 | 0.09 | 0.11 | -0.09 | 0.05 | |
Return on tangible assets | -0.02 | 0.11 | 0.12 | -0.11 | 0.07 | |
Graham Net | -3.54 | -3.59 | -2.67 | -3.23 | -2.35 | |
Working capital | 502.28K | 2.26M | -19.6M | 2.33M | 1.04M | |
Tangible asset value | 407.47M | 426.53M | 565.68M | 454.34M | 447.12M | |
Net current asset value | -120.68M | -119.12M | -145.73M | -125.5M | -120M | |
Invested capital | 0.59 | 0.56 | 0.42 | 0.53 | 0.54 | |
Average receivables | 27.1M | 2.41M | 2.62M | 2.93M | 2.85M | |
Average payables | 19.53M | 1.03M | 11.29M | 11.56M | 1.17M | |
Average inventory | 55.17M | 7.37M | 18.7M | 29.55M | 22.09M | |
Days sales outstanding | -90.66 | 14.54 | 11.66 | -18.39 | 24.55 | |
Days payables outstanding | 107.58 | 12.35 | 1.15K | 36.71 | 84.31 | |
Days of inventory on hand | 862.82 | 0 | 1.93K | 1.05K | 1.2K | |
Receivables turnover | -4.03 | 25.1 | 31.3 | -19.84 | 14.87 | |
Payables turnover | 3.39 | 29.55 | 0.32 | 9.94 | 4.33 | |
Inventory turnover | 0.42 | 0 | 0.19 | 0.35 | 0.31 | |
ROE | -0.03 | 0.14 | 0.15 | -0.14 | 0.08 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q4
Metric | History | 2021-09-30 | 2022-03-31 | 2022-09-30 | 2023-03-31 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.47 | 0.18 | 0.84 | 0.05 | 1.16 | |
Net income per share | 1.01 | 0.28 | -1.96 | 1.2 | -0.21 | |
Operating cash flow per share | 0.03 | 0.04 | 0.03 | 0.01 | -0.12 | |
Free cash flow per share | 0.03 | 0.04 | 0.03 | 0.01 | -0.12 | |
Cash per share | 0.93 | 0.46 | 0.5 | 0.33 | 0.52 | |
Book value per share | 15.18 | 14.77 | 12.12 | 12.64 | 11.73 | |
Tangible book value per share | 15.18 | 14.77 | 12.12 | 12.64 | 11.73 | |
Share holders equity per share | 15.18 | 14.77 | 12.12 | 12.64 | 11.73 | |
Interest debt per share | 6.46 | 6.44 | 6.44 | 6.41 | 6.4 | |
Market cap | 612.84M | 569.3M | 482.25M | 521.37M | 446.69M | |
Enterprise value | 732.84M | 689.3M | 602.25M | 641.36M | 566.69M | |
P/E ratio | 4.07 | 13.37 | -1.64 | 2.85 | -13.87 | |
Price to sales ratio | 11.2 | 86.04 | 15.33 | 265.83 | 10.15 | |
POCF ratio | 491.33 | 380.71 | 378.43 | 2.73K | -97.38 | |
PFCF ratio | 491.33 | 380.71 | 378.43 | 2.73K | -97.38 | |
P/B Ratio | 1.08 | 1.03 | 1.06 | 1.09 | 1 | |
PTB ratio | 1.08 | 1.03 | 1.06 | 1.09 | 1 | |
EV to sales | 13.39 | 104.18 | 19.14 | 327.01 | 12.87 | |
Enterprise value over EBITDA | 19.16 | 60.89 | -8.36 | 13.15 | -135.46 | |
EV to operating cash flow | 587.54 | 460.96 | 472.6 | 3.36K | -123.54 | |
EV to free cash flow | 587.54 | 460.96 | 472.6 | 3.36K | -123.54 | |
Earnings yield | 0.06 | 0.02 | -0.15 | 0.09 | -0.02 | |
Free cash flow yield | 0 | 0 | 0 | 0 | -0.01 | |
Debt to equity | 0.42 | 0.43 | 0.53 | 0.5 | 0.54 | |
Debt to assets | 0.34 | 0.35 | 0.41 | 0.4 | 0.42 | |
Net debt to EBITDA | 3.14 | 10.6 | -1.67 | 2.46 | -28.68 | |
Current ratio | 0.12 | 18.5 | 4.08 | 2.37 | 1.66 | |
Interest coverage | 67.32 | 16.79 | -52.55 | 15.62 | -1.08 | |
Income quality | 0.03 | 0.14 | -0.02 | 0 | 0.57 | |
Dividend Yield | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | |
Payout ratio | 0.66 | 2.28 | -0.33 | 0.53 | -3.04 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 18.59 | 9.73 | 23.11 | 18.5 | 7.47 | |
ROIC | 0.05 | 0.01 | -0.1 | 0.07 | -0.01 | |
Return on tangible assets | 0.05 | 0.02 | -0.13 | 0.08 | -0.01 | |
Graham Net | -2.5 | -2.54 | -2.58 | -2.77 | -2.35 | |
Working capital | -19.6M | 5.37M | 2.33M | 1.71M | 1.04M | |
Tangible asset value | 565.68M | 552.09M | 454.34M | 479.62M | 447.12M | |
Net current asset value | -145.73M | -121.73M | -125.5M | -124.59M | -120M | |
Invested capital | 0.42 | 0.43 | 0.53 | 0.5 | 0.54 | |
Average receivables | 2.66M | 4.22M | 4.38M | 3.02M | 2.79M | |
Average payables | 11.28M | 11.34M | 531.78K | 1.01M | 1.42M | |
Average inventory | 27.67M | 30.06M | 22.2M | 18.59M | 19M | |
Days sales outstanding | 4.55 | 77.29 | 8.83 | 135.73 | 5.36 | |
Days payables outstanding | 514.1 | 7.3 | 18.23 | 32.98 | 41.47 | |
Days of inventory on hand | 859.87 | 539.92 | 522.47 | 407.58 | 588.56 | |
Receivables turnover | 19.8 | 1.16 | 10.2 | 0.66 | 16.78 | |
Payables turnover | 0.18 | 12.33 | 4.94 | 2.73 | 2.17 | |
Inventory turnover | 0.1 | 0.17 | 0.17 | 0.22 | 0.15 | |
ROE | 0.07 | 0.02 | -0.16 | 0.1 | -0.02 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
THW Frequently Asked Questions
What is Tekla World Healthcare Fund stock symbol ?
Tekla World Healthcare Fund is a US stock , located in Boston of Ma and trading under the symbol THW
What is Tekla World Healthcare Fund stock quote today ?
Tekla World Healthcare Fund stock price is $13.23 today.
Is Tekla World Healthcare Fund stock public?
Yes, Tekla World Healthcare Fund is a publicly traded company.